Shandong Xinhua Pharmaceutical Company Limited operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shandong Xinhua Pharmaceutical Company Limited with three other
companies in this sector in China:
ChangChun High New Technology Industries
sales of 4.04 billion Chinese Renmimbi [US$597.55 million]
of which 85%
Apeloa Pharmaceutical Co Ltd
(5.55 billion Chinese Renmimbi [US$821.27 million]
of which 100%
was Health Care & Pharmaceutical), and
Shanxi Zhendong Pharmaceutical Co Ltd
(3.73 billion Chinese Renmimbi [US$552.02 million]
of which 101%
was Medicine Manufacture and Sale).
During the year ended December of 2017, sales at
Shandong Xinhua Pharmaceutical Company Limited were 4.52 billion Chinese Renmimbi (US$668.01 million).
increase of 12.5%
versus 2016, when the company's sales were 4.01 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Shandong Xinhua Pharmaceutical Company Limited
(and since 2012, sales have increased a total of 54%).
Sales of Pharmaceutical Intermediates and Others saw an increase
14.5% in 2017, from
497.06 million Chinese Renmimbi to 569.01 million Chinese Renmimbi.